Search Results | Blood | American Society of Hematology

1-20 of 259

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Xiaotian Zhang, Xinyu Wang, Xue Qing David Wang, Jianzhong Su, Nagireddy Putluri, Ting Zhou, Ying Qu, Mira Jeong, Anna Guzman, Carina Rosas, Yun Huang, Arun Sreekumar, Wei Li, Margaret A. Goodell

Blood (2020) 135 (11): 845–856.

DOI: https://doi.org/10.1182/blood.2019003330

Published: 2020

Includes: Supplemental data

Journal Articles

Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 856.

DOI: https://doi.org/10.1182/blood-2019-123328

Published: 2019

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

DOI: https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Chang Ki Min, MD PhD, Kihyun Kim, MD PhD, Seok Jin Kim, MD PhD, Dok Hyun Yoon, Sung-Soo Park, Seunghoon Han, MD PhD

Blood (2019) 134 (Supplement_1): 1847.

DOI: https://doi.org/10.1182/blood-2019-127643

Published: 2019

Journal Articles

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tomoyuki Tanaka, Kiyomi Morita, MD, Feng Wang, PhD, Latasha Little, Curtis Gumbs, Jairo Matthews, Courtney D. DiNardo, MDMSc, Tapan M. Kadia, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Guillermo Garcia-Manero, MD, P Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 17.

DOI: https://doi.org/10.1182/blood-2019-122274

Published: 2019

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

DOI: https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Guillermo Garcia-Manero, MD, Maciej Kaźmierczak, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Adriano Venditti, Silvia Mappa, MD, Riccardo Spezia, Lionel Ades, MD PhD

Blood (2019) 134 (Supplement_1): 2652.

DOI: https://doi.org/10.1182/blood-2019-125924

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

DOI: https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Lina Driouk, MD, Joanina Gicobi, Yusuke Kamihara, MD PhD, Kayleigh Rutherford, Glenn Dranoff, MD, Jerome Ritz, MD, Susanne H.C. Baumeister, MD

Blood (2019) 134 (Supplement_1): 1930.

DOI: https://doi.org/10.1182/blood-2019-130113

Published: 2019

Journal Articles

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Aleš Obr, MD PhD, Pavel Klener, Jr., Eva Kriegova, Dr, assoc prof, Zuzana Zemanova, PhD, Helena Urbankova, MSc, PhD, Andrea Jirkuvova, MD, Anna Petrackova, MSc, Barbora Cudova, Lenka Sedlarikova, MSc, VIT K Prochazka, MD, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3995.

DOI: https://doi.org/10.1182/blood-2019-123812

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

DOI: https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

DOI: https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd

Shuichiro Takashima, MD PhD, Maria L. Martin, PhD, Suze A. Jansen, Ya-Yuan Fu, PhD, Anastasiya Egorova, Chen Liu, MD PhD, Richard Kolesnick, MD, Caroline A. Lindemans, MD, Alan M. Hanash, MD PhD

Blood (2019) 134 (Supplement_1): 585.

DOI: https://doi.org/10.1182/blood-2019-130811

Published: 2019

Journal Articles

Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood . 2010;115(22):4478-4487.

Blood (2019) 134 (1): 95.

DOI: https://doi.org/10.1182/blood-2019-05-901223

Published: 2019

Journal Articles

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Blood (2018) 132 (Supplement 1): 920.

DOI: https://doi.org/10.1182/blood-2018-99-114442

Published: 2018

Journal Articles

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 5383.

DOI: https://doi.org/10.1182/blood-2018-99-111578

Published: 2018

Journal Articles

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Enrico Derenzini, MD PhD, Alessandra Rossi, PhD, Claudio Agostinelli, MD, Maura Rossi, PhD, Federica Melle, PhD, Giovanna Motta, PhD, Marco Fabbri, PhD, Tommaso Radice, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Valentina Tabanelli, MD, Stefano Fiori, MD, Annalisa Chiappella, MD, Alberto Agazzi, MD, Pier Luigi Zinzani, MD, Umberto Vitolo, Corrado Tarella, MD Prof, Stefano A. Pileri, MD PhD

Blood (2018) 132 (Supplement 1): 676.

DOI: https://doi.org/10.1182/blood-2018-99-118329

Published: 2018

Journal Articles

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Jessica M Salmon, PhD, Giovanna Pomilio, Donia M Moujalled, PhD, Sarah Macraild, Charis E Teh, PhD, Sewa Riajl, PhD, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MD, Paul G Ekert, Laurence Kraus-Berthier, Ioana Kloos, Marie Schoumacher, Daniel Gray, Andrew H Wei, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1426.

DOI: https://doi.org/10.1182/blood-2018-99-117403

Published: 2018

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

DOI: https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

Journal Articles

A Case-Control Study to Compare the Survival Benefits of Patients Who Suffer from Peripheral T-Cell Lymphoma (PTCL) Treated with Chidamide, a Histone Deacetylase Inhibitor, in China with a Historical Matched Cohort of Patients Treated with Conventional Therapy in Taiwan: Survival Advantage Is Demonstrated

Bor-Sheng Ko, MD PhD, Su-Peng Yeh, MD, Hsiao-Wen Kao, MD, Yuan-Bin Yu, MD, Shyh-Tyan Ou, PhD, Cheng-Shyong Chang, MD

Blood (2018) 132 (Supplement 1): 5367.

DOI: https://doi.org/10.1182/blood-2018-99-114738

Published: 2018

2 3 4 5

NARROW

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd

Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood . 2010;115(22):4478-4487.

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only